#### Edgar Filing: Fibrocell Science, Inc. - Form 4

Fibrocell Scie	ence, Inc.								
Form 4 September 09	2016								
								OMB A	PPROVAL
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								-	3235-0287
Check this if no longe subject to Section 16 Form 4 or Form 5 obligation may contin <i>See</i> Instruct 1(b).	er <b>STATEN</b> 5. Filed put s Section 17(	rsuant to S (a) of the F	ection Public U	<b>SECUI</b> 16(a) of th Itility Hol	<b>RITIES</b> ne Securi lding Cor	ties Excha	WNERSHIP OF nge Act of 1934, of 1935 or Secti 940	Estimated burden hou response	urs per
(Print or Type R	esponses)								
1. Name and Ac KIRK RANI	_	2. Issuer Name <b>and</b> Ticker or Trading Symbol Fibrocell Science, Inc. [FCSC]				5. Relationship of Reporting Person(s) to Issuer			
(Last)						(Chi	eck all applicable)		
C/O THIRD GROVE AV	SECURITY, LI ENUE	LC, 1881	(Month/) 09/07/2	Day/Year) 2016			Director Director (give below)		% Owner ner (specify
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)			1	<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li> Form filed by One Reporting Person</li> <li>_X_ Form filed by More than One Reporting</li> </ul>					
RADFORD,	VA 24141						Person		1 6
(City)	(State)	(Zip)	Tab	le I - Non-	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	ally Owned
	2. Transaction Date Month/Day/Year)	2A. Deeme Execution I any (Month/Da	Date, if	Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, -	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder: Repo	ort on a separate line	e for each cla	ass of sec	urities bene	ficially ow	ned directly	or indirectly		
reninder, repo					Perso inform requir	ns who res nation cont red to resp nys a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and A
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Se
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Acquired (A) of Disposed of (I (Instr. 3, 4, and	D)			
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title
Convertible Promissory Note	<u>(1)</u>	09/07/2016		Р	\$ 236,851		<u>(1)</u>	<u>(1)</u>	Common Stock
Convertible Promissory Note	<u>(1)</u>	09/07/2016		Р	\$ 7,325		<u>(1)</u>	<u>(1)</u>	Common Stock
Convertible Promissory Note	<u>(1)</u>	09/07/2016		Р	\$ 3,913,979		<u>(1)</u>	<u>(1)</u>	Common Stock
Convertible Promissory Note	(1)	09/07/2016		Р	\$ 2,604,345		<u>(1)</u>	<u>(1)</u>	Common Stock
Warrant to Purchase Common Stock	\$ 1.5	09/07/2016		Р	236,851		03/08/2017 <u>(1)</u>	09/07/2021	Common Stock
Warrant to Purchase Common Stock	\$ 1.5	09/07/2016		Р	7,325		03/08/2017(1)	09/07/2021	Common Stock
Warrant to Purchase Common Stock	\$ 1.5	09/07/2016		Р	3,913,979		03/08/2017(1)	09/07/2021	Common Stock
Warrant to Purchase Common Stock	\$ 1.5	09/07/2016		Р	2,604,345		03/08/2017 <u>(1)</u>	09/07/2021	Common Stock

### Edgar Filing: Fibrocell Science, Inc. - Form 4

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships				
	Director	10% Owner	Officer	Other	
KIRK RANDAL J C/O THIRD SECURITY, LLC 1881 GROVE AVENUE RADFORD, VA 24141		Х			

#### INTREXON CORP C/O LEGAL DEPARTMENT 20374 SENECA MEADOWS PARKWAY GERMANTOWN, MD 20876

Х

### **Signatures**

/s/ Randal J. Kirk, CEO of Intrexon Corporation	09/09/2016		
<u>**</u> Signature of Reporting Person	Date		
/s/ Randal J. Kirk	09/09/2016		
<u>**</u> Signature of Reporting Person	Date		

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The Convertible Promissory Notes bear interest at a rate of 4% per annum with a maturity date of the earlier of (i) September 7, 2026 and (ii) 180 days after the date on which the issuer's product candidate, FCX-007, is approved by the United States Food and Drug Administration. The Notes are convertible at the option of each holder into shares of common stock at a conversion price of \$1.13625. In

Administration. The Notes are convertible at the option of each holder into shares of common stock at a conversion price of \$1.1502. In connection with the purchase of the Notes, each holder also received a warrant to purchase one share of the issuer's common stock per one dollar invested at a price per share of \$1.50. The Notes and Warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively.

Randal J. Kirk controls Kapital Joe, LLC ("Kapital Joe"), Mascara Kaboom, LLC ("Mascara Kaboom") and NRM VII Holdings I, LLC (NRM VII Holdings"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d 3).

(NRM VII Holdings"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon Corporation ("Intrexon"). Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer

(3) owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.